Study guide

6.1 Acute Coronary Syndromes in ICU Patients

Board Certified Critical Care Pharmacist Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pathophysiology and Recognition of Critical Illness

1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness

2 Chapter 2: Medical Devices and Circulatory Support

2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care

3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management

3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation

4 Chapter 4: Vasoactive and Inotropic Therapy in Shock

4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock

5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)

5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness

6 Chapter 6: Cardiovascular Emergencies

6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias

7 Chapter 7: Pulmonary and Infectious Diseases in the ICU

7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU

8 Chapter 8: Neurocritical Care

8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury

9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies

9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy

10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition

10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral

11 Chapter 11: Quality, Safety, and Clinical Guidelines

11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions

12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine

12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management

13 Chapter 13: Treatment Planning and Care Coordination

13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education

6.1 Acute Coronary Syndromes in ICU Patients

Key Takeaways Explain This Topic AI

Type 2 myocardial infarction is frequently encountered in the ICU due to severe physiological stress; management must prioritize correcting the underlying supply-demand mismatch over routine aggressive antithrombotic therapy.

The cornerstone of medical management for Type 1 ACS includes dual antiplatelet therapy (DAPT) and therapeutic anticoagulation, balanced carefully against the patient's bleeding risk.

In patients presenting with NSTEMI, an early invasive strategy is strictly indicated if there is evidence of hemodynamic instability, refractory angina, heart failure, or life-threatening arrhythmias.

Fibrinolytic therapy in STEMI is generally reserved for situations where primary percutaneous coronary intervention (PCI) cannot be performed within the guideline-mandated 120-minute window.

Last updated: July 2026

Acute Coronary Syndromes in ICU Patients

Acute Coronary Syndromes (ACS) encompass a spectrum of clinical conditions ranging from unstable angina (UA) to non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI). In the critical care environment, diagnosing and managing ACS is uniquely challenging due to atypical presentations, concurrent severe illnesses, and competing risks of thrombosis and hemorrhage.

The Universal Definition of Myocardial Infarction

Understanding the distinction between different types of myocardial infarction is paramount in the ICU. The Fourth Universal Definition of Myocardial Infarction classifies MI into several types, with Type 1 and Type 2 being the most relevant for critical care practitioners.

Type 1 Myocardial Infarction

Type 1 MI is the classic acute coronary event caused by atherothrombotic plaque rupture, ulceration, or erosion resulting in intraluminal thrombus formation in one or more coronary arteries. This leads to decreased myocardial blood flow and ensuing myocyte necrosis. Management is focused on plaque stabilization, restoring coronary blood flow, and preventing further thrombosis.

Type 2 Myocardial Infarction

Type 2 MI is characterized by myocardial necrosis occurring secondary to a condition other than coronary plaque instability that causes a mismatch between myocardial oxygen supply and demand. In the ICU, this is extraordinarily common. Causes include severe hypoxemia, acute anemia, tachyarrhythmias, sustained hypotension, or severe hypertension.

Crucially, treating a Type 2 MI with aggressive antithrombotic therapy (as one would a Type 1 MI) can be harmful, especially if the underlying cause is a gastrointestinal bleed causing anemia and hypotension. The primary treatment for Type 2 MI is always correcting the underlying physiological derangement.

Diagnostic Approach in the Critically Ill

Patients in the ICU are often sedated, intubated, or unable to communicate classic symptoms like substernal chest pain. Therefore, diagnosis frequently relies on a high index of suspicion combined with objective data.

Electrocardiography (ECG): A 12-lead ECG should be obtained within 10 minutes of suspected ACS. Dynamic ST-segment changes, new left bundle branch block (LBBB), or new T-wave inversions strongly suggest acute ischemia.

Cardiac Biomarkers: High-sensitivity cardiac troponin (hs-cTn) assays are the standard of care. However, troponin elevation in the ICU is multifactorial and can be seen in sepsis, pulmonary embolism, renal failure, and heart failure. A rising or falling pattern of troponin is more indicative of acute injury than a chronically elevated level.

Echocardiography: Bedside echocardiography is invaluable for identifying new regional wall motion abnormalities, assessing global ventricular function, and ruling out other causes of shock or chest pain (e.g., aortic dissection, pericardial effusion).

Pharmacological Management of Type 1 ACS

Once a Type 1 ACS is identified, prompt medical therapy is required to halt thrombus propagation.

Antiplatelet Therapy

Dual antiplatelet therapy (DAPT) is the standard of care. This consists of aspirin and a P2Y12 inhibitor.

Aspirin: A loading dose of 162-325 mg (chewed) followed by 81 mg daily.

P2Y12 Inhibitors: Options include clopidogrel, ticagrelor, or prasugrel.

Ticagrelor is preferred over clopidogrel in ACS due to more rapid and potent platelet inhibition, but causes more dyspnea.

Prasugrel is generally reserved for patients undergoing percutaneous coronary intervention (PCI) and is contraindicated in patients with a history of stroke or TIA.

Anticoagulation

Systemic anticoagulation is initiated to prevent further thrombus formation. Options include:

Unfractionated Heparin (UFH): Preferred in the ICU due to its short half-life and reversibility, especially in hemodynamically unstable patients or those likely to undergo CABG.

Enoxaparin: A low molecular weight heparin (LMWH). Renally cleared, so dosing must be adjusted or avoided in acute kidney injury.

Bivalirudin: A direct thrombin inhibitor, often used during PCI, particularly in patients with a history of heparin-induced thrombocytopenia (HIT).

Anti-Ischemic Therapy

Beta-Blockers: Initiate orally within 24 hours if there are no signs of heart failure, low output state, risk for cardiogenic shock, or other contraindications. They reduce myocardial oxygen demand.

Nitrates: Sublingual or intravenous nitroglycerin can be used for ongoing ischemic pain, control of hypertension, or management of pulmonary edema. Avoid in right ventricular infarction or recent use of phosphodiesterase inhibitors.

Statins: High-intensity statin therapy (e.g., atorvastatin 80 mg) should be initiated as early as possible to stabilize plaques.

  • Interventional Strategies
  • ST-Segment Elevation MI (STEMI)

The goal in STEMI is immediate reperfusion.

Primary PCI is the treatment of choice. The goal is a door-to-balloon time of less than 90 minutes (or less than 120 minutes if transferred to a PCI-capable facility).

Fibrinolysis (e.g., tenecteplase, alteplase) is indicated only if PCI cannot be performed within 120 minutes of first medical contact and there are no contraindications. Fibrinolysis is rarely used in modern urban ICU settings but is critical knowledge for rural or transport medicine.

Non-ST-Segment Elevation ACS (NSTEMI/UA)

The timing of angiography depends on risk stratification.

Immediate Invasive Strategy (< 2 hours): Indicated for patients with hemodynamic instability, cardiogenic shock, severe left ventricular dysfunction, refractory angina despite medical therapy, or life-threatening arrhythmias (e.g., VT/VF).

Early Invasive Strategy (< 24 hours): Indicated for patients with elevated troponin, dynamic ST-segment changes, or a high GRACE risk score (>140).

Clinical Scenario

A 68-year-old male is admitted to the ICU with severe community-acquired pneumonia requiring mechanical ventilation. On day 2, his blood pressure drops to 75/40 mmHg, and his heart rate increases to 130 bpm (sinus tachycardia). A routine morning chemistry panel shows a new troponin I elevation to 2.5 ng/mL (normal < 0.04). His hemoglobin has dropped from 11 g/dL to 7 g/dL due to a newly diagnosed large gastric ulcer bleed. An ECG shows sinus tachycardia with non-specific ST-T wave changes.

Management: This patient has a Type 2 myocardial infarction driven by severe oxygen supply-demand mismatch (anemia and hypotension/shock). Administering a heparin drip and dual antiplatelet therapy for this elevated troponin would be catastrophic due to his active GI bleed. The correct management involves aggressive fluid resuscitation, blood transfusion, proton pump inhibitors, and endoscopic evaluation to stop the bleeding, which will correct the ischemia.